In the BioHarmony Drug Report Database
Dapsone
Aczone (dapsone) is a small molecule pharmaceutical. Dapsone was first approved as Aczone on 2005-07-07. It is used to treat aids-related opportunistic infections, dermatitis herpetiformis, lepromatous leprosy, and relapsing polychondritis in the USA. It is known to target hydroxymethyldihydropterin pyrophosphokinase-dihydropteroate synthase. Dapsone’s patent is valid until 2033-11-18 (FDA).
Trade Name
|
Aczone |
|---|---|
Common Name
|
dapsone |
ChEMBL ID
|
CHEMBL1043 |
Indication
|
aids-related opportunistic infections, dermatitis herpetiformis, lepromatous leprosy, relapsing polychondritis |
Drug Class
|
Image (chem structure or protein)